



OncoMethylome Sciences Reports 2009 Half-Year Results

Continued Strong Clinical Data for Key Products

Liege (Belgium) – Regulatory Release – August 27, 2009, 8:00 CET – OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) published its financial results today for the first half of 2009, ending on June 30, 2009.

In the first half of 2009, OncoMethylome continued to develop and validate several tests for cancer detection and personalized cancer treatment. During this period the following main advances were made:

- Significantly advanced the novel blood-based colorectal cancer screening test
 - Made test more robust and automatable
 - Continued to validate test on numerous clinical samples
 - Completed 2000-patient trial
 - Initiated new 5000-patient trial
 - Followed-up interest from various potential distribution partners
- Presented supplemental clinical data further showing the ability of OncoMethylome's test to detect bladder cancer in urine samples (sensitivity 90%, specificity 93%)
- Provided MGMT companion diagnostic testing services for several new pharmaceutical drug trials (RTOG/Avastin, Merck/Cilengitide)
- Initiated several new research collaborations with big Pharma and leading oncology centers to identify new companion diagnostic biomarkers for major oncology drug classes.

H1 2009 financial highlights (versus H1 2008)

Key Figures (EUR thousands, except number of shares and per share data):

	June 30, 2009	June 30, 2008
Revenues	1,268	1,521
Operating loss (EBIT)	-6,529	-6,218
Net loss	-6,340	-5,700
Earnings per share, basic and diluted (€)	-0.48	-0.48
Number of outstanding shares	13,185,614	11,808,822
Cash and cash equivalents	23,745	25,394

Revenues

Revenues decreased by 17% to EUR 1.3 million from EUR 1.5 million for the same period in 2008, mainly due to one-time up-front fees and milestone fees on deals which occurred in 2008. There were no up-front or milestone fees received in 2009.

Costs and Profitability

Total research and development expenses for the first half of 2009 were EUR 5.6 million compared with EUR 5.8 million for the first half of 2008. This 4% decrease resulted from

a reduction in external R&D collaboration expenses offset in part by an increase in clinical trials.

Selling, general and administrative expenses increased to EUR 2.1 million in the first half of 2009 from EUR 1.8 million in H1 2008. This increase is mainly due to the expansion of the business development activities.

As a result of the expansion in business development activities, the total operating costs increased by 2% in H1 2009 compared to H1 2008.

Cash Position

OncoMethylome's cash and cash equivalents amounted to EUR 23.7 million at June 30, 2009. Total net cash consumed in the first 6 months of 2009 decreased to EUR 6.9 million compared to a total net cash consumption of EUR 7.7 million in the same period of 2008.

Outlook for H2 2009

"We continue to have strong scientific results on all of our key new products in development" stated Mr. Herman Spolders, CEO of OncoMethylome. "Most importantly, the recent clinical data is coming from non-invasive samples on test versions that have been simplified and improved to run in commercial laboratories. Most of the R&D efforts in H1 2009 were focused on enhancing the ease of use of the blood-based colorectal cancer screening test for commercial purposes and validating the test on ever-increasing clinical sample sets. Colorectal cancer is one of the most common cancers that most often can be successfully-treated if detected early. However, current screening tests on the market result in less than 40% of the colorectal cancers being detected at an early-stage. We are thus very encouraged by the current scientific results of our non-invasive test for the screening of colorectal cancer."

OncoMethylome's current revenues are highly dependent on fees from certain new deals and milestones, for which the exact timing is uncertain. For the full year 2009 OncoMethylome expects to increase its spending, mainly for clinical trials. As a result, OncoMethylome expects the loss of the full year 2009 to be higher than that of 2008

Statutory auditor's limited review report

" We have reviewed the accompanying consolidated statement of financial position of OncoMethylome Sciences S.A. and its subsidiaries, as of 30 June 2009 and the related consolidated income statement, statement of comprehensive income, changes in equity and cash flows for the six month period then ended, as well as the condensed explanatory notes. The board of directors is responsible for the preparation and presentation of this condensed consolidated interim financial information in accordance with IAS 34 as adopted by the European Union. Our responsibility is to express a conclusion on this condensed consolidated interim financial information based on our review.

We conducted our review in accordance with the recommendation of the Belgian Institute of Company Auditors related to the performance of reviews. Accordingly, it involved principally analysis, comparison and discussion of the condensed consolidated interim financial information and, accordingly, was less extensive in scope than an audit of that information.

Our review did not reveal any matters requiring correction of the condensed consolidated interim financial information for it to have been prepared, in all material respects, in accordance with IAS 34 as adopted by the European Union."

Zaventem - August 26, 2009

The Statutory Auditor
BDO Atrio Réviseurs d'Entreprises Soc. Civ. SCRL
Represented by Bert Kegels

Complete financial statements:

To download the 2009 interim report, go to
<http://www.oncomethylome.com/investors/financials.htm>

OncoMethylome Reporting Calendar

November 5, 2009 – Q3 2009 business update
March 11, 2010 – Full year 2008 results
May 6, 2010 – Q1 2010 business update
May 28, 2010 – Annual general shareholders' meeting
August 26, 2010 – Half year 2010 results

About OncoMethylome Sciences

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence.

OncoMethylome boasts a broad product development pipeline consisting of over ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johnson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, Merck KGaA and Qiagen. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA).

Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands).

For more information please contact:

Philip Devine
Tel. +32 4 364 2070
ir@oncomethylome.com
or visit: www.oncomethylome.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different.